Latest Robert Austrian Stories
BETHESDA, Md., April 22, 2013 /PRNewswire-USNewswire/ -- The National Foundation for Infectious Diseases will host the 16(th )Annual Conference on Vaccine Research, April 22-24, 2013, at the Hyatt Regency Inner Harbor in Baltimore, MD. This three-day conference presents high-quality, current reports of scientific progress and best practices in both invited presentations and submitted oral abstracts and posters. The conference brings together the diverse disciplines involved in the...
BETHESDA, Md., May 4, 2012 /PRNewswire-USNewswire/ -- The National Foundation for Infectious Diseases will host the 15th Annual Conference on Vaccine Research, May 7-9, 2012, at the Hyatt Regency Inner Harbor in Baltimore, MD. This three-day conference presents high-quality, current reports of scientific progress via invited presentations and submitted abstracts. As the premier venue for cutting edge learning, effective data sharing, and scientific collaboration on issues related...
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria. The findings, which could improve vaccines against pneumonia, appear in the September/October issue of mBio, the online journal of the American Society for Microbiology. Until recently, scientists thought that antibodies work against pneumococcal bacteria by killing them with the help of immune cells. However, several years ago, Einstein...
BEIJING, Jan. 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the submission of the applications to commence human clinical trials for its 23-valent and 24-valent pneumococcal polysaccharides vaccines to the Chinese State Food Drug Administration (SFDA) on January 31, 2011. The preclinical studies were completed and showed good safety and efficacy profile in animal models. Sinovac independently...
BETHESDA, Md., April 26 /PRNewswire/ -- Scientists at the 13th Annual Conference on Vaccine Research (ACVR), sponsored by the National Foundation for Infectious Diseases (NFID), will reflect on the remarkable growth of vaccine biotechnology in the last several decades and focus on the growing number of challenging illnesses that may become vaccine-preventable or vaccine-treatable in the coming years. According to Susan J. Rehm, MD, Medical Director for NFID, "In addition to the reality...
